SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-008934
Filing Date
2023-03-21
Accepted
2023-03-21 16:07:15
Documents
13
Period of Report
2023-03-16
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tnya-20230316.htm   iXBRL 8-K 75992
2 EX-3.1 tnya-ex3_1.htm EX-3 335502
  Complete submission text file 0000950170-23-008934.txt   578467

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT tnya-20230316_lab.xml EX-101.LAB 14432
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT tnya-20230316_pre.xml EX-101.PRE 11882
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT tnya-20230316.xsd EX-101.SCH 2494
7 EXTRACTED XBRL INSTANCE DOCUMENT tnya-20230316_htm.xml XML 5088
Mailing Address 171 OYSTER POINT BLVD., SUITE 500 SOUTH SAN FRANCISCO CA 94080
Business Address 171 OYSTER POINT BLVD., SUITE 500 SOUTH SAN FRANCISCO CA 94080 415-865-2066
Tenaya Therapeutics, Inc. (Filer) CIK: 0001858848 (see all company filings)

IRS No.: 813789973 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40656 | Film No.: 23749786
SIC: 2836 Biological Products, (No Diagnostic Substances)